CVS Caremark Study Finds $100 Mil. Opportunity For Medicaid In Generic Switching Without Patient Consent
This article was originally published in The Pink Sheet Daily
Executive Summary
With big patent expirations approaching in 2011 for Lipitor, Zyprexa and Plavix, CVS Caremark is promoting aggressive generic substitution policies by state Medicaid programs as a way to save more than $100 million.